Daniel Coderre

Sep 08, 2016

Génome Québec has appointed Daniel Coderre as its president and CEO. Before coming to Génome Québec, Coderre served as rector of the Institut National de la Recherche Scientifique. He has also held positions on nearly twenty committees, boards of directors, and commissions on science, technology, and innovation.

More Like This

Mar 21, 2018

Grannum Sant

Exosome Diagnostics has appointed Grannum Sant as its head of medical affairs. Sant holds an appointment as Professor of Urology at Tufts University, where he has spent more than two decades. He has also served various leadership positions in research and professional societies, including a term as President of the New England Section of the American Urological Association.

Outside of academia, Sant worked as a pharma medical affairs and clinical development executive, serving as a vice president of medical affairs at both Sanofi-Aventis US, and at Genzyme. Most recently he was the medical affairs lead for OPKO Health.

Mar 20, 2018

Jennifer Lee, Vikram Jog

Fluidigm said in a filing with the US Securities and Exchange Commission that Jennifer Lee, the company's current vice president, controller, and principal accounting officer, is resgining as of March 29. Vikram Jog, Fluidigm's current chief financial officer, will serve as principal accounting officer in addition to his current role. Jog has served as Fluidigm's CFO since February 2008.

Mar 20, 2018

Elaine Mardis

Elaine Mardis has been named president-elect of the American Association for Cancer Research for 2018-19. Her appointment will start next month in conjunction with the AACR annual meeting in Chicago, and she will become AACR president in April of 2019. Mardis holds the Nationwide Foundation Endowed Chair of Genomic Medicine and is the co-executive director of the Institute for Genomic Medicine at Nationwide Children's Hospital, and a professor of pediatrics at the Ohio State University College of Medicine. She holds a bachelor's degree and a PhD from the University of Oklahoma.  

Mar 20, 2018

Aaron Mendes, Debora Thompson, Sharon Terry

Luna DNA has hired Aaron Mendes as vice president of marketing and Debora Thompson as VP of business strategy and operation. The genomic and medical research database company also named Genetic Alliance CEO Sharon Terry to its advisory board. Thompson is a former director of market strategy and innovation for clinincal genomics at Illumina. Mendes is an entrepreneur who founded and later sold digital marketing intelligence startup Quantio. 

Mar 20, 2018

Mark Stenhouse

Exact Sciences has appointed Mark Stenhouse to the new role of president for its flagship product Cologuard, a non-invasive stool DNA-based test for early detection of colorectal cancer. Stenhouse, who is currently serving as vice president of the US immunology group at AbbVie, will assume this new position on April 2. At AbbVie, Stenhouse leads the sales and marketing teams for the anti-inflammatory drug Humira. He has spent nearly 30 years at Abbott Laboratories/AbbVie, where he was first hired for a field sales position. He became national sales director in the US immunology-gastroenterology franchise, and rose to marketing director, followed by senior director of commercial initiatives. In 2010, Stenhouse was appointed a general manager within the company before being promoted to vice president. 

Mar 20, 2018

George Cardoza, Sharon Virag

NeoGenomics announced the appointments of George Cardoza as president of the Pharma Services Division, and Sharon Virag as chief financial officer. The position of president of the Pharma Services Division is a newly created position. Cardoza, who has served as chief financial officer since 2009, will lead a division that grew revenues 69 percent to $8.7 million last year. The division also includes a new lab in Rolle, Switzerland that was added last year to meet Pharma Services demand. Virag, who is succeeding Cardoza in the chief financial officer role, was previously vice president, corporate finance and chief accounting officer, at Aetna. Her appointment is effective on March 27.

Mar 16, 2018

Gerald Herman

Bruker has appointed Gerald Herman as interim CFO effective March 17. Herman was also recently appointed as principal accounting officer for the company, and he will assume his additional responsibilities as interim CFO following the departure of current CFO Anthony Mattacchione, whose resignation was announced in February. Herman joined the company in 2016 as vice president and corporate controller. Prior to that, he held senior executive positions with various publicly traded companies including Parexel International and Presstek.

Mar 12, 2018

Phil Febbo

Illumina has appointed Phil Febbo as chief medical officer. Starting March 26, 2018, Febbo will be responsible for developing and executing on Illumina's strategy to drive genomic testing into healthcare practice.

Prior to Joining Illumina, Febbo has served as CMO at Genomic Health, and before that he served as professor of medicine and urology at the University of California, San Francisco, where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer. While at UCSF, Febbo was the co-leader of the Prostate Cancer Program at the Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology. He holds a BA degree in biology from Dartmouth College, received his MD at UCSF, and completed his internal medicine residency at the Brigham and Women's Hospital. 

Mar 12, 2018

Rob Brainin, Hannes Smàrason

Rob Brainin has been appointed as WuXi NextCode's CEO, replacing Hannes Smàrason, who will stay on as a senior advisor and plans to pursue other entrepreneurial opportunities. Most recently, Brainin was the firm's executive vice president and COO. Prior to that, he held positions at Illumina, Thermo Fisher, Life Technologies, and Invitrogen. Brainin holds a degree in economics from Emory University and a JD degree from Harvard Law School.

Mar 08, 2018

Arne Materna

CosmosID announced today that it appointed Arne Materna as its VP of product. Materna previously worked at Qiagen, where he directed the product management organization responsible for a high-growth segment of Qiagen's portfolio of bioinformatics products. Prior to Qiage, Materna held managment and senior roles at CLC bio, Pacific Biosciences, and MIT. 

Mar 07, 2018

David Cameron

Former UK prime minister David Cameron became a consultant for Illumina last month in order to help the company raise awareness about the benefits of genomics. Prior to his appointment, Cameron told the UK's Advisory Committee on Business Appointments that his main role would be to assist Illumina's engagement with foreign governments and stakeholders as it works and expands outside the UK, and that he would help with the formation of a new international advisory board and chair that board, which has not been established yet.

Mar 07, 2018

John Mattick

Genomics England has appointed John Mattick as its first CEO. Mattick will join Genomics England in June from Australia's Garvan Institute of Medical Research, which he has led since 2012. Mattick is noted for his scientific contributions to understanding the human genome, specifically his work showing that most of the genome is not evolutionary 'junk' but instead is devoted to an extensive RNA regulatory system that organizes human development. He will continue his academic career while in the UK at the University of Oxford's Green Templeton College, where he has been elected to a senior research fellowship for one day a week.

Mar 07, 2018

Paul Limburg

Exact Sciences has appointed Paul Limburg as co-chief medical officer. Limburg is a gastroenterologist and a professor of medicine at the Mayo Clinic, and serves as a co-leader of the Cancer Prevention and Control program within the Mayo Clinic Cancer Center. While at Mayo, he has also served as medical director of its global business solutions unit, and as medical director of several of its health and well-being programs. Limburg will advise Exact Sciences on research opportunities to inform, expand, and accelerate the adoption of effective colon cancer screening options such as Cologuard. He will continue to serve as a gastroenterologist with Mayo Clinic's Division of Gastroenterology and Hepatology, co-leader of the Cancer Prevention and Control program within Mayo Clinic Cancer Center, and principal investigator for the NCI-funded cancer prevention network clinical trials consortium.

Mar 02, 2018

Kim Albizati

Molecular Assemblies has appointed Kim Albizati as VP of chemistry and biochemistry. Prior to Molecular Assemblies, Albizati served senior direcctor of chemistry, manufactoring, and controls at Dart Neuroscience. In addition, Albizati has served as executive director of chemistry at Agouron and leadership positions at Pfizer. 

Mar 01, 2018

Guillaume Bouhours

BioMérieux has appointed Guillaume Bouhours as corporate vice-president, CFO, and a member of its executive committee. He replaces Claire Giraut, who is retiring, and will head the firm's finance, purchasing, and information systems departments. Bouhours was previously CFO at Faiveley Transport, a railway equipment manufacturer based in France.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.